AUTHOR=González-Iglesias Eva , Ochoa Dolores , Navares-Gómez Marcos , Zubiaur Pablo , Aldama Marina , Torre Tamara de la , Ríos-Rodríguez Marta de los , Soria-Chacartegui Paula , Rodríguez-Lopez Andrea , Abad-Santos Francisco , Novalbos Jesús 

TITLE=Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414059

DOI=10.3389/fphar.2024.1414059

ISSN=1663-9812

ABSTRACT=<sec><title>Introduction</title><p>Ezetimibe inhibits cholesterol uptake by modulation of intestinal sterol absorption. Currently, although some studies have shown alterations in ezetimibe levels caused by alterations in the <italic>ABCG5</italic>, <italic>ABCG8</italic>, <italic>NPC1L1</italic> or <italic>UGT1A1</italic> genes, there are no pharmacogenetic guidelines to confirm these biomarkers. The aim of this work was to evaluate the effect of 49 variants in 22 pharmacogenes related to metabolism and transport.</p></sec><sec><title>Methods</title><p>A total of 96 healthy volunteers from four bioequivalence clinical trials of ezetimibe as monotherapy or in combination with simvastatin were studied. Blood samples were extracted for unconjugated ezetimibe plasma quantification and genotyping.</p></sec><sec><title>Results and Discussion</title><p>No association of metabolizing enzyme variants with ezetimibe pharmacokinetic parameters was found. The results show some trends in the univariate analysis for <italic>ABCB1</italic> rs2032582 or <italic>ABCC2</italic> rs2273697 and C<sub>max</sub> (<italic>p univariate</italic> (<italic>p</italic><sub><italic>uv</italic></sub>) = 0.056 and 0.087, respectively), which finally reach significance in the multivariate analysis (<italic>p multivariate</italic> (<italic>p</italic><sub><italic>mv</italic></sub>) = 0.049 and 0.048, respectively). Nevertheless, these results need to be validated in future studies.</p></sec>